Skip to main content
Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc. — Investor Relations & Filings

Ticker · EBS ISIN · US29089Q1058 LEI · 549300YW6TUOX8BE5103 US Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2013-01-18 Director's Dealing
Country US United States of America
Listing US EBS

About Emergent BioSolutions Inc.

https://emergentbiosolutions.com/

Emergent BioSolutions Inc. is a life sciences company specializing in solutions for public health threats. The company develops, manufactures, and delivers medical countermeasures for national security and public health preparedness, addressing threats such as anthrax, smallpox, botulism, and Ebola. In addition to its biodefense portfolio, Emergent provides commercial products for endemic health crises, notably the opioid epidemic. The company also offers contract development and manufacturing services through strategic partnerships, leveraging its specialized capabilities to support biopharmaceutical innovators, governments, and non-governmental organizations.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2013-01-18 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company announced preliminary unaudited financial results and guidance, and that the full press release is attached as an exhibit. The document length is short (2223 characters), and it primarily serves as an announcement of the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, initial announcements of quarterly or periodical financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2013-01-07 English
4 Filing
Director's Dealing
2012-12-28 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a press release announcing a license agreement with VaxInnate Corporation. The document length is 2657 characters, which is relatively short and mainly contains an announcement of an event rather than detailed financial data or comprehensive reporting. There are no financial statements or detailed financial analysis included. The document is not an earnings release, annual report, or interim report. It is a regulatory filing announcing a material event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-12-28 English
4 Filing
Director's Dealing
2012-12-14 English
4 Filing
Director's Dealing
2012-12-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.